- Home
- OABI vs WIA Comparison
OABI vs WIA Comparison
Compare OABI & WIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- WIA
- Stock Information
- Founded
- OABI 2012
- WIA 2003
- Country
- OABI United States
- WIA United States
- Employees
- OABI N/A
- WIA N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- WIA Trusts Except Educational Religious and Charitable
- Sector
- OABI Health Care
- WIA Finance
- Exchange
- OABI Nasdaq
- WIA Nasdaq
- Market Cap
- OABI 236.1M
- WIA 192.9M
- IPO Year
- OABI N/A
- WIA N/A
- Fundamental
- Price
- OABI $1.94
- WIA $8.37
- Analyst Decision
- OABI Strong Buy
- WIA
- Analyst Count
- OABI 3
- WIA 0
- Target Price
- OABI $7.00
- WIA N/A
- AVG Volume (30 Days)
- OABI 643.9K
- WIA 39.2K
- Earning Date
- OABI 08-06-2025
- WIA 01-01-0001
- Dividend Yield
- OABI N/A
- WIA 12.29%
- EPS Growth
- OABI N/A
- WIA N/A
- EPS
- OABI N/A
- WIA N/A
- Revenue
- OABI $26,744,000.00
- WIA N/A
- Revenue This Year
- OABI N/A
- WIA N/A
- Revenue Next Year
- OABI $45.02
- WIA N/A
- P/E Ratio
- OABI N/A
- WIA N/A
- Revenue Growth
- OABI 27.07
- WIA N/A
- 52 Week Low
- OABI $1.22
- WIA $7.56
- 52 Week High
- OABI $4.96
- WIA $8.91
- Technical
- Relative Strength Index (RSI)
- OABI 57.48
- WIA 58.40
- Support Level
- OABI $1.93
- WIA $8.30
- Resistance Level
- OABI $2.11
- WIA $8.41
- Average True Range (ATR)
- OABI 0.14
- WIA 0.05
- MACD
- OABI -0.00
- WIA -0.01
- Stochastic Oscillator
- OABI 47.24
- WIA 48.75
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.